Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Eli Lilly Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (73)
Cancellation by sponsor (67)
Australian public assessment report (AusPar) (20)
Prescription medicine registration (20)
Designation or determination (4)
Prescription medicine decision summary (4)
Prescription medicine evaluation (4)

Date

2026 (4)
2025 (29)
2024 (21)
2023 (21)
2022 (15)
2021 (10)
2020 (4)
2019 (34)
2018 (14)
2017 (1)
2016 (2)
2015 (7)
2014 (2)
2013 (4)
2012 (1)
2011 (2)
2010 (1)
2008 (2)
2007 (1)
2006 (1)
2004 (1)
2002 (2)
1999 (4)
1998 (1)
1996 (2)
1992 (4)
1991 (2)

Search

Sponsor content

192 result(s) found, displaying 111 to 120

TALTZ (Eli Lilly Australia Pty Ltd)

6 March 2020

Prescription medicine registration

Active ingredients: ixekizumab.
GEMZAR gemcitabine 1g (as hydrochloride) powder for injection, vial Cancelled under Section 30(1)(c) of the Act

25 November 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
GEMZAR gemcitabine 200mg (as hydrochloride) powder for injection, vial Cancelled under Section 30(1)(c) of the Act

25 November 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
ZYPREXA olanzapine 15mg tablet bottle Cancelled under Section 30(1)(c) of the Act

18 September 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
ZYPREXA olanzapine 20mg tablet bottle Cancelled under Section 30(1)(c) of the Act

18 September 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
TRULICITY (Eli Lilly Australia Pty Ltd)

19 July 2019

Prescription medicine registration

Active ingredients: dulaglutide (rch).
AusPAR: Baricitinib

17 July 2019

Australian public assessment report (AusPar)

Australian Public Assessment for Baricitinib
TALTZ ixekizumab 80 mg/mL solution for injection prefilled pen (253893)

6 September 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for TALTZ ixekizumab 80 mg/mL solution for injection prefilled pen.
TALTZ ixekizumab 80 mg/mL solution for injection prefilled syringe (253892)

6 September 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for TALTZ ixekizumab 80 mg/mL solution for injection prefilled syringe.
LILLY OLANZAPINE IM olanzapine 10mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd

Pages

First page
Previous page
…
Page 8
Page 9
Page 10
Page 11
Current page 12
Page 13
Page 14
Page 15
Page 16
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.